GTC Anticipates Reaching U.S. Market In 2009 With Human Antithrombin ATryn
This article was originally published in The Pink Sheet Daily
Executive Summary
Company tells “The Pink Sheet” DAILY it will seek indications for larger patient populations than initial target of hereditary antithrombin deficiency.
You may also be interested in...
FDA Advisors To Determine Need For Post-Marketing Study Of GTC Biotherapeutics’ ATryn
The antithrombin’s efficacy and safety profile suggest ATryn has a clear path to approval.
FDA Advisors To Determine Need For Post-Marketing Study Of GTC Biotherapeutics’ ATryn
The antithrombin’s efficacy and safety profile suggest ATryn has a clear path to approval.
GTC Completes BLA For Recombinant Clot Buster Atryn
Phase II study in sepsis DIC indication is actively enrolling, GTC says.